Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple injection cure tennis elbow? new study aims to find out.

NCT ID NCT06040203

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether injecting platelet-rich plasma (PRP) into the elbow can reduce pain and improve function in people with tennis elbow that hasn't gotten better with other treatments. 240 adults will receive either PRP with white blood cells, PRP without white blood cells, or a saltwater placebo injection. The goal is to see which approach works best for easing symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients with epicondylitis of the elbow: 1. Patients with clinical picture of epicondylitis; 2. Duration of symptoms \> 3 months 3. Ultrasound picture of short or long radial extensor carpal tendinopathy; 4. Age \> 18 and \< 65 5. Both sexes; 6. Failure, defined as persistence of symptoms, of other conservative treatments for at least 3 months; 7. Hemoglobin \> 11 g/dl; 8. Platelet count \> 150,000 plt/mm3 (Recently performed CBC examination); 9. Negative serological tests for HBsAg, HCV Ab, HIV-1-2 Ab 10. No clinically significant electrocardiographic changes (Recently performed ECG); 11. Ability and consent of the patient to actively participate in clinical follow-up; 12. Signature of informed consent. Exclusion Criteria: 1. Patients undergoing previous surgical treatment on the epicondylar tendons; 2. Patients undergoing epicondylar infiltration in the previous 6 months; 3. Inability of patients to actively participate in clinical follow-up; 4. Incapacitated patients; 5. Patients with states of immunodepression; 6. Patients with fibromyalgia; 7. Ongoing systemic inflammatory diseases (stabilized outcomes of such diseases are not considered absolute contraindications); 8. Patients with uncontrolled thyroid metabolic disorders; 9. Patients abusing alcoholic beverages, drugs or medications; 10. Patients who have taken NSAIDs in the 3 days prior to blood collection; 11. Patients with coagulation problems or with ongoing antiplatelet therapy that cannot be suspended for at least 3 days prior to blood draw; 12. Patients with cardiovascular disease for whom a 300-mL blood draw would be contraindicated; 13. Positive serological tests for HBsAg, HCV Ab, HIV-1-2 Ab 14. Other current elbow diseases (osteoarthritis, prevalence of symptomatology due to epitrochleitis, stiff elbow, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tennis elbow are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto Ortopedico Rizzoli

    RECRUITING

    Bologna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.